Multivariate analysis of overall survival.

<p>^† Reference group</p><p>* PS = Performance Status (ECOG)</p><p>** Entered as a continuos variable</p><p>The risk ratio refers to moving from the reference group to the other group or changing one step in parameters entered as continuous variables.</p><p>Multivariate analysis of overall survival.</p

Pre-treatment characteristics and cell-free DNA levels in all cohorts.

<p>Data have been rounded to nearest 100.</p><p># total number with available samples,</p><p>* only cancer patients</p><p>**One sample excluded because of visible hemolysis</p><p>*** All p-values for differences between each cancer cohort and the control group</p><p>Pre-treatment characteristics and cell-free DNA levels in all cohorts.</p

Kaplan Major Plots of OS probabilities.

<p>A. Patients are grouped by quartiles of cfDNA (from the right) lowest, second lowest, second highest and highest quartile of cfDNA. The median OS according to cfDNA quartiles were; 10.2 months (95% CI 8.9–12.8), 7.8 months (5.7–9.3), 5.0 months (4.3–6.0) 3.5 months (3.0–3.9), respectively. B. Patients are grouped by the upper normal range as defined by mean cfDNA+2SD in the control group (7100 alleles per ml.) Low risk group (full line), Median OS, 10.2 months (8.3–11.7). High risk group (dotted line) Median OS, 5.2 months (4.6–5.9). HR 1.78, p = 0.0006.</p

A and B. Cell free DNA concentrations in colorectal cancer cohorts and healthy controls.

<p><b>A</b> depicts Box and whisker plots with 25%, 50%, 75% percentiles, upper and lower adjacent values and outliers (dots). Horizontally the four clinical trial cohorts and control group, vertically the cfDNA concentration on a logarithmic scale. C cetuximab study, GemCap GemCap cohort, PG PG study cohort, T TIRASMUS study cohort, Controls healthy control group. <b>B</b> Shows a receiver operating curve (ROC) estimating the performance of cfDNA to discriminate between colorectal cancer patients and controls. The AUC was 0.9486, (95% CI 0.9182–0.9679, p<0.00001).</p

Misclassification of patients relative to the reference interval.

<p>Dividing the patients in three subgroups based on the reference interval produces “Below”, “Ref. interval” and “Above”. The table indicates the number of patients in each subgroup. The graph shows the same numbers in % for the subgroups “Below” and “Above”. The values in the “Misclassification” box are the number of patients misclassified at 2–3pm relative to 7–8am.</p

Total impact of resting time and diurnal variation on the biochemical compounds.

<p>The figure shows the change in mean value (in %) relative to the mean under the reference conditions (7–9am, resting time 15–30 minutes) for the four components A) albumin, B) thyrotropin, C) calcium and D) sodium. The shadowed background field indicates the limits for the MAB (1/3×SD_pop). The values above the columns are the number of patients in each interval.</p

Data on the study subjects according to <i>CD300LG</i> rs72836561 CC, CT, and TT genotype.

<p>Mean and 95% confidence interval. P-values obtained from Students t-test.</p>1<p>Median and interquartile range. P-value obtained from Students t-test of log-transformed data.</p>2<p>Median and interquartile range. P-value obtained from linear regression on rank normalized data adjusted for age.</p><p>Data on the study subjects according to <i>CD300LG</i> rs72836561 CC, CT, and TT genotype.</p

Meta-analysis of the effect of the C-allele of <i>TMEM154</i>-rs6813195 on insulinogenic index in 6,486 individuals from the Inter99 study (n = 5,181), Health 2008 study (n = 592), ADIGEN controls (n = 246), ADIGEN obese cases (n = 165) and Danish Family study (n = 302).

<p>Gray diamond represents combined change per risk allele and the 95% confidence interval. Gray squares represent effects size estimates (beta coefficients) in single studies sized according to their weight in the meta-analyses. The horizontal lines through the gray squares represent the 95% confidence interval. ob, obese. <i>p</i>, <i>P</i>-value. CI, confidence interval. W(fixed), study weight in the fixed effect meta-analysis.</p

Meta-analysis of the effect of the G-allele of <i>FAF1</i>-rs17106184 on 2-hour serum insulin in 6,260 individuals from the Inter99 study (n = 5,547), ADIGEN controls (n = 246), ADIGEN obese cases (n = 165) and Danish Family study (n = 302).

<p>Gray diamond represents combined change per risk allele and the 95% confidence interval. Gray squares represent effects size estimates (beta coefficients) in single studies sized according to their weight in the meta-analyses. The horizontal lines through the gray squares represent the 95% confidence interval. ob, obese. <i>p</i>, <i>P</i>-value. CI, confidence interval. W(fixed), study weight in the fixed effect meta-analysis.</p

Meta-analysis of the effect of the C-allele of <i>TMEM154</i>-rs6813195 on disposition index in 6,486 individuals from the Inter99 study (n = 5,181), Health 2008 study (n = 592), ADIGEN controls (n = 246), ADIGEN obese cases (n = 165) and Danish Family study (n = 302).

<p>Gray diamond represents combined change per risk allele and the 95% confidence interval. Gray squares represent effects size estimates (beta coefficients) in single studies sized according to their weight in the meta-analyses. The horizontal lines through the gray squares represent the 95% confidence interval. ob, obese. <i>p</i>, <i>P</i>-value. CI, confidence interval. W(fixed), study weight in the fixed effect meta-analysis.</p